Positioning of old and new biologicals and small molecules in the treatment of inflammatory bowel diseases

Jason Reinglas, Lorant Gonczi, Zsuzsanna Kurt, Talat Bessissow, Peter L. Lakatos

Research output: Contribution to journalReview article

15 Citations (Scopus)


The past decade has brought substantial advances in the management of inflammatory bowel diseases (IBD). The introduction of tumor necrosis factor (TNF) antagonists, evidence for the value of combination therapy, the recognition of targeting lymphocyte trafficking and activation as a viable treatment, and the need for early treatment of high-risk patients are all fundamental concepts for current modern IBD treatment algorithms. In this article, authors review the existing data on approved biologicals and small molecules as well as provide insight on the current positioning of approved therapies. Patient stratification for the selection of specific therapies, therapeutic targets and patient monitoring will be discussed as well. The therapeutic armamentarium for IBD is expanding as novel and more targeted therapies become available. In the absence of comparative trials, positioning these agents is becoming difficult. Emerging concepts for the future will include an emphasis on the development of algorithms which will facilitate a greater understanding of the positioning of novel biological drugs and small molecules in order to best tailor therapy to the patient. In the interim, anti-TNF therapy remains an important component of IBD therapy with the most real-life evidence and should be considered as first-line therapy in patients with complicated Crohn's disease and in acute-severe ulcerative colitis. The safety and efficacy of these 'older' anti-TNF therapies can be optimized by adhering to therapeutic algorithms which combine clinical and objective markers of disease severity and response to therapy.

Original languageEnglish
Pages (from-to)3567-3582
Number of pages16
JournalWorld journal of gastroenterology
Issue number32
Publication statusPublished - Aug 28 2018


  • Biologic
  • Inflammatory bowel disease
  • Positioning
  • Small molecule
  • Therapeutic

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint Dive into the research topics of 'Positioning of old and new biologicals and small molecules in the treatment of inflammatory bowel diseases'. Together they form a unique fingerprint.

  • Cite this